Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

41,269 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Ectopic JAK-STAT activation enables the transition to a stem-like and multilineage state conferring AR-targeted therapy resistance.
Deng S, Wang C, Wang Y, Xu Y, Li X, Johnson NA, Mukherji A, Lo UG, Xu L, Gonzalez J, Metang LA, Ye J, Tirado CR, Rodarte K, Zhou Y, Xie Z, Arana C, Annamalai V, Liu X, Vander Griend DJ, Strand D, Hsieh JT, Li B, Raj G, Wang T, Mu P. Deng S, et al. Among authors: xu l, xu y. Nat Cancer. 2022 Sep;3(9):1071-1087. doi: 10.1038/s43018-022-00431-9. Epub 2022 Sep 5. Nat Cancer. 2022. PMID: 36065066 Free PMC article.
Author Correction: Ectopic JAK-STAT activation enables the transition to a stem-like and multilineage state conferring AR-targeted therapy resistance.
Deng S, Wang C, Wang Y, Xu Y, Li X, Johnson NA, Mukherji A, Lo UG, Xu L, Gonzalez J, Metang LA, Ye J, Tirado CR, Rodarte K, Zhou Y, Xie Z, Arana C, Annamalai V, Liu X, Vander Griend DJ, Strand D, Hsieh JT, Li B, Raj G, Wang T, Mu P. Deng S, et al. Among authors: xu l, xu y. Nat Cancer. 2022 Oct;3(10):1271. doi: 10.1038/s43018-022-00458-y. Nat Cancer. 2022. PMID: 36241729 Free PMC article. No abstract available.
Targeting cellular heterogeneity with CXCR2 blockade for the treatment of therapy-resistant prostate cancer.
Li Y, He Y, Butler W, Xu L, Chang Y, Lei K, Zhang H, Zhou Y, Gao AC, Zhang Q, Taylor DG, Cheng D, Farber-Katz S, Karam R, Landrith T, Li B, Wu S, Hsuan V, Yang Q, Hu H, Chen X, Flowers M, McCall SJ, Lee JK, Smith BA, Park JW, Goldstein AS, Witte ON, Wang Q, Rettig MB, Armstrong AJ, Cheng Q, Huang J. Li Y, et al. Among authors: xu l. Sci Transl Med. 2019 Dec 4;11(521):eaax0428. doi: 10.1126/scitranslmed.aax0428. Sci Transl Med. 2019. PMID: 31801883 Free PMC article.
Therapeutic potential of ReACp53 targeting mutant p53 protein in CRPC.
Zhang Y, Xu L, Chang Y, Li Y, Butler W, Jin E, Wang A, Tao Y, Chen X, Liang C, Huang J. Zhang Y, et al. Among authors: xu l. Prostate Cancer Prostatic Dis. 2020 Mar;23(1):160-171. doi: 10.1038/s41391-019-0172-z. Epub 2019 Aug 30. Prostate Cancer Prostatic Dis. 2020. PMID: 31471556 Free PMC article.
Characterization of a castrate-resistant prostate cancer xenograft derived from a patient of West African ancestry.
Patierno BM, Foo WC, Allen T, Somarelli JA, Ware KE, Gupta S, Wise S, Wise JP Sr, Qin X, Zhang D, Xu L, Li Y, Chen X, Inman BA, McCall SJ, Huang J, Kittles RA, Owzar K, Gregory S, Armstrong AJ, George DJ, Patierno SR, Hsu DS, Freedman JA. Patierno BM, et al. Among authors: xu l. Prostate Cancer Prostatic Dis. 2022 Sep;25(3):513-523. doi: 10.1038/s41391-021-00460-y. Epub 2021 Oct 13. Prostate Cancer Prostatic Dis. 2022. PMID: 34645983 Free PMC article.
41,269 results
You have reached the last available page of results. Please see the User Guide for more information.